ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Bridging AI and Chemotherapy: Translating Precision Medicine into Improved Patient Outcomes

Dr. Koyel Misra*, Dr. Subhajit Mukherjee, Dr. Sanchita Sarkar, Dr. Bipasha Mridha Ghosh, Dr. Srabani Guria Das & Dr. Siladitya Laha

NSHM Knowledge Campus Durgapur West Bengal, India

DOI: https://dx.doi.org/10.51244/IJRSI.2025.1210000179

Received: 06 November 2025; Accepted: 14 November 2025; Published: 14 November 2025

ABSTRACT

Second- and third-generation chemotherapeutic agents have transformed modern oncology by improving therapeutic efficacy, tolerability, and compatibility with targeted and immunotherapeutic approaches. Despite these advances, persistent challenges—such as drug resistance, cumulative toxicity, long-term quality-of-life effects, and disparities in treatment access—continue to limit optimal outcomes. This narrative review explores the integration of artificial intelligence (AI) into the ongoing evolution of chemotherapeutics as a strategy to address these barriers. We critically analyze developments in pharmacologic innovation, clinical performance, and AI-driven enhancements in drug design, dose optimization, response prediction, and toxicity surveillance. Finally, we identify current limitations and outline future research directions aimed at achieving more precise, equitable, and patient-centered chemotherapy in the era of intelligent oncology.

Keywords: Second-generation chemotherapy, Third-generation chemotherapy, Toxicity prediction, Quality of life; Health equity; Cancer pharmacology

INTRODUCTION

Cancer continues to be a major global health burden. Traditional chemotherapy remains a cornerstone of treatment, particularly in advanced or metastatic settings. Generational classification (first, second, third) reflects enhancements in targeting, delivery, and toxicity profiles. However, even "next-generation" chemotherapies face significant challenges in efficacy, safety, and equitable deployment [1,2].

Artificial intelligence (AI), machine learning (ML), and other computational approaches have begun to influence oncology in imaging, biomarker discovery, treatment planning, and outcome prediction. Integrating AI into the development and clinical use of chemotherapeutics holds promise for making chemotherapy more precise, adaptive, and patient-friendly [3]. This review frames the current state of second- and third-generation chemotherapies, and then explores how AI integration could address their limitations and reshape future directions.

Defining Second and Third Generation Chemotherapeutics (with AI Context)

Second-generation chemotherapeutics are drugs developed after the first wave of traditional chemotherapy agents (like alkylating agents, antimetabolites, and natural products)[4,5]. These second-generation agents were designed to be more selective, less toxic, or more effective in overcoming resistance seen with earlier treatments.

Third-generation chemotherapeutics represent a further evolution, often incorporating molecular targeting**,** precision oncology**,** or biologic agents. These therapies are typically designed based on a deep understanding of cancer biology, including genetic and molecular abnormalities [6].

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Key Characteristics

As cancer therapies continue to evolve, the transition from second- to third-generation agents reflects significant advancements in drug design, delivery, and clinical application. Second-generation therapies typically represent refinements of earlier treatments, offering modest improvements in efficacy, selectivity, and toxicity profiles. In contrast, third-generation agents introduce novel mechanisms of action and are increasingly integrated with biologics and immunotherapies, aiming for greater precision and impact [7,8]. The integration of artificial intelligence (AI) into this progression marks a transformative shift. By leveraging large datasets and computational modeling, AI enhances multiple aspects of drug development and clinical application—from identifying novel compounds to optimizing dosing strategies and predicting patient-specific responses. The table below compares key features across these therapeutic generations and outlines how AI can further augment their effectiveness and safety.

Feature	Second Generation	Third Generation	AI-enabled enhancements
Mechanism	Modified versions of older agents (e.g. prodrugs, changed substituents)	Novel mechanisms (e.g. microtubule stabilizers, new topoisomerase inhibitors)	AI can suggest novel scaffolds or mechanisms via in silico screening
Selectivity	Moderate improvements in targeting	Greater specificity via synergy with biologics	AI can predict which tumor genotypes respond best, refining selectivity
Toxicity	Reduced relative to first-gen	Significant acute toxicity; long-term damage risks	AI models can predict patient-specific toxicity risk
Delivery / Dosing	Oral, prodrugs, modified-release formulations	Liposomes, nanoparticles, dose-dense regimens	AI-driven dose optimization and scheduling
Compatibility	Some integration with targeted/biologics	Frequent combination with immunotherapy/targeted agents	AI can aid in rational combination design (synergy prediction)

Illustrative Examples

Second-generation chemotherapeutics mark an important advancement in cancer treatment, improving upon first-generation drugs by enhancing safety, tolerability, and ease of administration. These agents aim to maintain or increase therapeutic efficacy while minimizing adverse effects, making treatment more manageable for patients. Notable examples—such as oral etoposide, carboplatin, and capecitabine—illustrate how modifications in formulation, toxicity profile, and tumor selectivity have translated into more convenient and patient-friendly therapies [9,10].

Second-Generation Chemotherapeutics

Second-generation chemotherapeutic agents represent a significant evolution in cancer treatment, building upon the foundations of earlier drugs to enhance safety, convenience, and clinical outcomes. These agents were designed to retain or improve therapeutic efficacy while reducing adverse effects and simplifying administration. The following examples illustrate key advances achieved through this generation of chemotherapeutic development.

These agents were developed as improved or modified versions of first-generation drugs, focusing on better tolerability, more convenient administration, and sometimes improved pharmacokinetics or reduced toxicity [11].

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Oral Etoposide is a topoisomerase II inhibitor developed as an oral formulation of the intravenous drug, offering increased convenience for outpatient or home-based therapy. It is commonly used in the treatment of small cell lung cancer, testicular cancer, and other solid tumors. The oral form maintains therapeutic activity while improving patient compliance due to ease of administration [12,13].

Carboplatin, a platinum-based agent, was developed as a less toxic alternative to cisplatin. It exhibits reduced nephrotoxicity, ototoxicity, and emetogenicity. Clinically, it is widely used in the treatment of ovarian, lung, and head and neck cancers. Its improved safety profile makes it easier to administer, particularly in elderly patients or those with renal impairment, due to fewer hydration requirements [14].

Capecitabine is an antimetabolite and a prodrug of 5-fluorouracil (5-FU), designed to be activated preferentially in tumor tissues through the enzyme thymidine phosphorylase. It is used primarily in breast and colorectal cancers. The oral route offers greater convenience, and the tumor-selective activation helps reduce systemic toxicity compared to intravenous 5-FU [15,16].

In NSCLC, platinum-doublet regimens combined with paclitaxel or gemcitabine became standard in stage III/IV disease, owing to better disease control metrics compared to older regimens. However, survival improvements have been modest.

In an AI-augmented paradigm, one can envision:

The use of machine learning and artificial intelligence is becoming increasingly important in the design of fourth-generation chemotherapeutics. These technologies enable the rapid screening of large chemical libraries to identify novel compounds with improved therapeutic windows, optimizing efficacy while minimizing toxicity.

In parallel, patient-specific molecular data is being utilized to predict the likelihood of response to third-generation chemotherapeutic agents. This approach allows for the personalization of treatment regimens, ensuring that patients receive therapies most likely to be effective based on their individual tumor profiles [17,18,19].



Fig1. AI-Driven Framework for Overcoming Drug Resistance in Chemotherapy [20]

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Clinical Performance and Comparative Outcomes (with AI Insights)

Clinical performance and comparative outcomes provide critical insights into the real-world effectiveness, safety, and overall value of chemotherapeutic agents across different cancer types. Evaluating these parameters helps determine not only the therapeutic success but also the quality of life and treatment sustainability for patients. With the integration of artificial intelligence (AI), these assessments are becoming more precise, enabling data-driven comparisons, predictive modeling, and personalized optimization of treatment strategies [21,22].

NSCLC as a Benchmark

Non–small cell lung cancer (NSCLC) has long served as a benchmark for evaluating advances in chemotherapeutic strategies, given its high prevalence and well-established treatment paradigms. Comparative studies across drug generations in NSCLC provide valuable insights into the evolution of efficacy, tolerability, and survival outcomes. As research progresses, the integration of artificial intelligence offers new opportunities to refine treatment selection and optimize therapeutic benefit for individual patients.

Meta-analyses (e.g. by Grossi et al.) suggest that third-generation doublets (e.g. cisplatin + docetaxel) often yield higher response rates and progression-free survival (PFS) than second-generation regimens, though gains in overall survival (OS) are frequently modest. Some long-term trials (e.g. WJTOG0105) showed minimal OS difference despite early PFS benefits.

With AI, one could refine patient selection to those likeliest to derive OS gain, perhaps shifting whom one applies third-generation regimens to, and thereby maximizing benefit while reducing unnecessary toxicity [23].

Broader Clinical Patterns

In the evolving landscape of cancer treatment, understanding broader clinical patterns is essential for optimizing patient outcomes. Traditional metrics such as response rates, progression-free survival (PFS), disease-free survival (DFS), overall survival, and quality of life (QoL) remain central to evaluating the effectiveness of therapies. However, while newer treatment regimens—particularly third-generation agents—have shown promise in improving some of these outcomes, challenges persist in translating clinical gains into meaningful benefits for every patient. Artificial intelligence (AI) has the potential to enhance this process by offering more personalized insights. The table below outlines key clinical observations and highlights how AI could play a transformative role in refining and individualizing cancer care [24].

Clinical Measure	Observation	Potential AI Role
Response rates	Frequently higher with third-gen agents	Predict per-patient probability of response
PFS / DFS	Improved in several tumors	Predict duration until resistance or progression
Overall survival	Often only modest gains	Stratify patients likely to benefit
Quality of life	Sometimes poorer due to toxicity	Model trade-offs in QoL vs survival on individual basis

AI models (e.g., combining imaging, genomics, clinical parameters) can better stratify patients, enabling “AI-guided chemo prescription” rather than one-size-fits-all regimens.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Toxicity, Long-Term Impacts & AI Risk Mitigation

Toxicity and long-term side effects remain major challenges in the clinical use of chemotherapeutic agents, often limiting dosing intensity and compromising patient quality of life. Understanding and managing these adverse effects are crucial for achieving optimal therapeutic outcomes. With the advent of artificial intelligence, predictive modeling and real-time monitoring now offer powerful tools to anticipate toxicity risks, personalize dosing strategies, and implement early interventions—ultimately enhancing both safety and treatment durability [25].

Acute and Chronic Toxicities

Acute and chronic toxicities remain pivotal considerations in the administration of advanced chemotherapeutic regimens, often determining treatment feasibility and long-term patient outcomes. While third-generation agents have improved efficacy, their use is frequently constrained by significant hematologic and organ-related side effects. Emerging applications of artificial intelligence and machine learning now offer a transformative approach—enabling early prediction of adverse drug reactions, individualized risk assessment, and proactive management strategies to minimize toxicity and enhance treatment safety [26].

Third-generation regimens are associated with notable hematologic (neutropenia, thrombocytopenia) and neurologic (peripheral neuropathy) toxicities, among others. Supportive care burden and hospitalization rates escalate. Chronic organ damage (renal, cardiac, hepatic) and secondary cancers are additional risks.

AI/ML models have shown promise in predicting adverse drug reactions (ADRs) in oncology patients. A recent meta-analysis pooled 17 studies (93,248 patients) and found pooled sensitivity ~0.82 and specificity ~0.84 in ADR prediction models.This suggests AI could be a tool for preemptively identifying patients at high risk and guiding preventive strategies or dose adjustments [27].



Fig2. Personalizing Conventional Therapy with AI Integration [28]

Long-Term Health and Survivorship

Long-term health and survivorship have become increasingly important as advancements in cancer therapy lead to improved survival rates. Beyond achieving remission, attention is now focused on the lasting physical and biological consequences of treatment, which can profoundly affect quality of life. Artificial intelligence–driven longitudinal modeling offers a promising avenue to anticipate these late effects, integrating diverse data sources to personalize follow-up care and promote healthier, more informed survivorship pathways.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Survivorship issues—such as fertility loss, organ damage, secondary malignancies, and epigenetic consequences—are underexplored in many trials. AI-based longitudinal modeling (e.g. combining genomic, clinical, lifestyle data) could help forecast late effects and guide monitoring plans [29].

Social and Ethical Considerations

The growing convergence of artificial intelligence and next-generation chemotherapeutics brings transformative potential—but also introduces profound social and ethical questions. As cancer care becomes increasingly data-driven and technologically complex, issues surrounding cost, equity, and transparency gain urgency. The high financial burden of advanced therapies, coupled with the additional expense of AI integration, risks widening global disparities in access to care. Furthermore, challenges in informed consent and algorithmic bias demand robust ethical governance, ensuring that innovation advances responsibly and benefits patients across diverse populations [30].

The integration of artificial intelligence into next-generation chemotherapeutic development introduces not only scientific and clinical advances but also complex social and ethical challenges. Issues of cost, accessibility, and transparency increasingly shape the landscape of modern oncology, influencing who benefits from these innovations. Moreover, the potential for algorithmic bias underscores the need for equitable AI design and rigorous ethical oversight to ensure that technological progress translates into fair and inclusive healthcare outcomes for all patient populations.

The financial burden of next-generation treatment regimens is already substantial, with costs reaching tens of thousands of U.S. dollars per cycle. The integration of AI-driven designs further adds to these expenses. Additionally, informed consent becomes more complex, as clinicians must explain AI-influenced decisions to patients, requiring greater transparency and understanding. Access to such advanced treatments and technologies also raises equity concerns, particularly in low- and middle-income countries (LMICs), where the high cost of drugs and the lack of AI infrastructure may limit availability and accessibility.

AI systems themselves can exacerbate inequities—if training data are biased toward high-resource settings, predictions may underperform in underrepresented populations. Ethical frameworks and fairness auditing will be essential [31].

Implications for Human Life: Balancing Survival, Quality and AI

Advances in chemotherapy and AI-driven personalization are redefining the boundaries between survival and quality of life in cancer care. While extending lifespan remains a central goal, equal emphasis is now placed on preserving functional well-being and minimizing treatment burdens. The integration of AI offers a means to achieve this balance—optimizing therapeutic choices, anticipating adverse effects, and tailoring care to individual needs—ultimately supporting a more humane and holistic approach to cancer survival.

Survival vs Quality of Life

The tension between prolonging survival and maintaining quality of life remains a central dilemma in modern oncology. While newer chemotherapeutic agents can modestly extend lifespan, these benefits often come at the cost of increased toxicity and reduced daily functioning. Emerging AI-based decision support tools offer a path toward more personalized, values-driven care—helping patients and clinicians visualize individual risk–benefit profiles and make treatment choices aligned with personal priorities and well-being.

Even when third-generation agents extend survival, their impact on subjective quality of life (QoL) can be negative. In elderly or frail patients, aggressive chemotherapy [32] may sacrifice independence. AI-based decision aids could help patients and clinicians model individualized trade-offs: e.g. “Would a 2-month median OS gain be worth the projected 30% chance of grade 3 neuropathy in you?”

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Reproductive, Psychological, and Social Consequences

Fertility impairment is a major concern, especially for younger patients undergoing chemotherapy. Artificial intelligence may play a role in developing risk models that predict the likelihood of germline damage based on cumulative drug exposures, allowing for more informed fertility preservation strategies.

Additionally, the psychological impacts of chemotherapy—such as depression, anxiety, and post-traumatic stress disorder—are often overlooked in clinical trials. AI-powered patient-reported outcome measure (PROM) monitoring tools have the potential to identify early signs of emotional distress and prompt timely interventions, improving overall patient care.

Comparative Summary: Strengths, AI-Augmented, and Limitations

Third-generation chemotherapy offers several significant advantages. It is associated with higher response rates and improved disease control, and it integrates more effectively with modern targeted therapies and immunotherapies. These agents also benefit from advanced delivery and dosing strategies, including the use of liposomes and nanoparticles, which can enhance drug bioavailability and reduce some side effects [33].

However, these advancements are accompanied by notable challenges. Third-generation chemotherapeutics can lead to increased toxicity, particularly in vulnerable populations such as the elderly or those with comorbidities. Despite improvements in disease control, overall survival gains are often marginal. The high cost and logistical complexity of these treatments pose further barriers, especially in low-resource settings. Resistance remains a major issue, and the lack of precise predictive markers limits the ability to tailor therapies effectively. Access disparities also prevent many patients from benefiting equally from these innovations.

Artificial intelligence has the potential to address several of these limitations and augment the value of third-generation chemotherapy. Predictive models powered by AI can forecast treatment response and toxicity risk, allowing for more personalized and safer therapeutic decisions. AI also facilitates drug discovery and lead optimization through virtual screening, and it supports rational design of combination therapies by predicting synergistic effects. Furthermore, AI can enhance clinical research through adaptive trial design and real-time patient monitoring, and it enables personalized dosing schedules based on individual pharmacokinetics and tumor biology.

Despite its promise, the integration of AI into oncology is not without limitations. The quality of input data, including issues of heterogeneity and missingness, can compromise model performance. Many AI models function as "black boxes," making their predictions difficult to interpret and validate clinically. Bias in training datasets can lead to unequal outcomes across populations. Regulatory challenges and a lack of standardized validation processes further complicate implementation. Additionally, ethical and legal questions about accountability remain unresolved, and integrating AI tools into existing clinical workflows continues to be a complex challenge, requiring careful consideration of data privacy, clinician training, and the balance between automation and human judgment.

Resistance Mechanisms and AI-Assisted Mitigation

Cancer drug resistance remains a major barrier to the long-term effectiveness of chemotherapeutic regimens, often leading to treatment failure and disease progression. Tumor cells can develop resistance through multiple mechanisms, including genetic mutations, drug efflux, and pathway adaptations. Artificial intelligence offers promising strategies to address this challenge by predicting resistance patterns, identifying alternative therapeutic targets, and guiding adaptive treatment plans—enabling more precise and dynamic approaches to overcome or delay resistance [34].

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Common Resistance Mechanisms

Chemotherapeutic resistance remains a significant challenge in cancer treatment. One of the primary mechanisms involves the upregulation of drug efflux pumps, such as P-glycoprotein, which actively transport drugs out of cancer cells, reducing their intracellular concentration and effectiveness. Additionally, many tumors develop enhanced DNA repair capabilities or exhibit increased tolerance to DNA damage, allowing them to survive genotoxic stress induced by chemotherapy. Mutations in drug targets or reprogramming of signaling pathways can also render treatments ineffective. Furthermore, tumor heterogeneity and plasticity—where cancer cells within the same tumor exhibit diverse genetic or phenotypic profiles—contribute to inconsistent responses and eventual resistance.

Emerging Strategies (AI-Enabled)

To combat these resistance mechanisms, several emerging strategies are being explored, many of which are supported or enhanced by artificial intelligence. Combination therapies, particularly those integrating traditional chemotherapeutics with targeted agents like PARP inhibitors, are showing promise in overcoming resistance. AI can assist in biomarker-based patient preselection, ensuring that therapies are matched to individuals most likely to benefit. Reinforcement learning models are being employed to optimize sequential or dose-dense chemotherapy regimens based on real-time patient response [35]. Additionally, AI is being used to identify resistance-modulating agents that could restore sensitivity to chemotherapy. More advanced approaches, such as AI-based counterfactual prediction frameworks using multi-omics model ensembles, are being developed to simulate alternative treatment pathways [36] tailored to a specific patient's molecular context, offering a powerful tool for personalized therapy design.

Future Research Directions

Future research in chemotherapy is increasingly being shaped by the integration of artificial intelligence, offering unprecedented opportunities to enhance drug development, personalize treatment, and improve patient outcomes. AI-driven approaches are enabling more precise therapeutic design, adaptive clinical trials, and individualized treatment strategies, while also addressing challenges such as drug resistance and toxicity management. Alongside these scientific advances, attention to policy, equity, and ethical implementation will be essential to ensure that these innovations benefit patients broadly and responsibly.

AI-Driven Therapeutic Development

Artificial intelligence is transforming the development of chemotherapeutic agents through the use of generative models, reinforcement learning, and in silico screening techniques. These approaches are enabling the design of novel cytotoxic scaffolds with optimized safety and efficacy profiles. AI is also being integrated with nanomedicine to facilitate tumor-targeted drug delivery using smart particles, improving therapeutic precision while minimizing systemic toxicity. In early-phase clinical trials, AI supports dose escalation strategies, patient stratification, and endpoint prediction, leading to more efficient and adaptive trial designs.

Personalized Oncology

AI plays a central role in advancing personalized oncology by integrating diverse data types—including genomics, transcriptomics, proteomics, radiomics, and clinical information—to build predictive models for treatment response, toxicity risk, and overall survival. These tools can be used to prospectively tailor chemotherapy regimens, selecting the most appropriate agents, doses, and schedules for individual patients. Additionally, AI enables adaptive modifications during treatment, such as dose adjustments or regimen changes, in response to early biomarker signals, enhancing therapeutic effectiveness and minimizing adverse effects.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Resistance and Recovery

Understanding and managing resistance is critical to long-term treatment success. AI-driven time-series modeling of longitudinal multi-modal data can help unravel tumor plasticity and mechanisms of reversible resistance. This knowledge supports the strategic use of approaches such as drug holidays, sequential therapies, or adaptive cycling, all guided by AI to delay or prevent resistance. Furthermore, AI can be leveraged to develop supportive care strategies aimed at mitigating chemotherapy-induced toxicity and improving recovery trajectories, thereby enhancing patient quality of life and treatment adherence.

Health Policy, Equity, and Clinical Practice

From a systems perspective, AI integration into chemotherapy must be accompanied by comprehensive policy and practice changes. Cost-effectiveness modeling can evaluate the value of AI-enhanced strategies compared to standard care, guiding resource allocation. To ensure equitable access, frameworks must be developed to support AI deployment in low-resource settings, addressing technological and infrastructure barriers. Inclusivity in clinical trials and AI training datasets is essential to avoid algorithmic bias and ensure generalizability. Clinical guidelines should be updated to reflect the role of AI in treatment decisions, emphasizing evidence-based, transparent integration. Finally, establishing clear regulatory pathways and transparency standards will be vital for the safe, ethical, and effective adoption of AI in chemotherapy practice.

Limitations of This Review

This review is a narrative rather than a systematic one, which introduces the potential for bias in the selection of articles and sources. The scope is intentionally broad, and as such, it does not provide specialty-specific recommendations for particular cancer types such as breast, colorectal, or pediatric cancers. The discussion on artificial intelligence is largely forward-looking and speculative; many of the concepts presented are in early development stages and lack mature clinical validation. Additionally, there is no standardized evidence grading system, such as GRADE, applied in this review. Future research should aim to adopt a more systematic and transparent methodology to strengthen the reliability and applicability of findings.

CONCLUSION

The evolution from first- to third-generation chemotherapies has brought major advances in cancer treatment, yet also introduced new challenges in toxicity, resistance, and diminishing survival gains. The next frontier lies in harnessing artificial intelligence to transform chemotherapy development, personalization, and monitoring. AI holds the potential to enable more precise, adaptive, and patient-centered therapeutic strategies. However, realizing this potential requires rigorous validation, careful management of data quality and bias, strong ethical frameworks, and a commitment to equitable access. The future of chemotherapy will not be defined by stronger drugs alone, but by smarter ones—guided by AI—where success is measured not only by prolonged survival, but by holistic patient well-being and fairness in care.

REFERENCES

1. Çiçin, F. N., & Sayın, S. (2023). Understanding artificial intelligence and applications in oncology: Narrative review. Journal of Oncological Sciences, 10(1), 39–46. https://doi.org/10.37047/jos.2023-98875
2. Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., et al. (2009). Meta-analysis evaluating the role of third-generation agents in first-line chemotherapy for advanced non-small-cell lung cancer. The Oncologist, 14(10), 1030–1039. https://theoncologist.onlinelibrary.wiley.com
3. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity. https://doi.org/10.1007/s11030-021-10222-7
4. Liu, W., Zhang, T., Zhang, Q., Yang, Y., Zhang, J., & Liu, X. (2022). A systematic review and meta-analysis of neoadjuvant chemo-immunotherapy in stage III non-small-cell lung cancer. BMC Pulmonary Medicine, 22, 490. https://doi.org/10.1186/s12890-022-02292-5

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

5. Mehta, A., Dobersch, S., Romero-Olmedo, A. J., & Barreto, G. (2015). Diagnostic and therapeutic implications of epigenetics in lung cancer. Cancer and Metastasis Reviews, 34(2), 229–241. https://pubmed.ncbi.nlm.nih.gov
6. Putt, K. S., Chen, G. W., Pearson, J. M., Sandhorst, J. S., Hoagland, M. S., Kwon, J. T., et al. (2016). Targeted activation of procaspase-3 as a strategy for personalized anticancer therapy. ACS Central Science, 2(7), 430–439. https://doi.org/10.1021/acscentsci.6b00165
7. Roberti, A., Valdes, A. F., Torrecillas, R., Fraga, M. F., & Fernandez, A. F. (2019). Nanomedicine and epigenetics in oncology: A clinical perspective. Clinical Epigenetics, 11, 81. https://clinicalepigeneticsjournal.biomedcentral.com
8. Smith, R. A., & Brown, J. (2019). A clinical review of triplet versus doublet third-generation chemotherapy in NSCLC. Lung Cancer Research. https://pubmed.ncbi.nlm.nih.gov
9. Soon, Y. Y., Stockler, M. R., Askie, L. M., & Boyer, M. J. (2009). Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. Journal of Clinical Oncology, 27(20), 3277–3283. https://doi.org/10.1200/JCO.2008.20.2761
10. Wang, L., Song, Y., Wang, H., Zhang, X., Wang, M., He, J., Li, S., Zhang, L., Li, K., & Cao, L. (2023). Advances of artificial intelligence in anticancer drug design: A review of the past decade. Pharmaceuticals, 16(2), 253. https://doi.org/10.3390/ph16020253
11. Wang, Y., Li, H., Wang, S., & Tang, Z. (2020). Platinum-based chemotherapeutics with dual inhibition and targeting mechanisms: Recent developments. Journal of Inorganic Biochemistry, 204, 110914. https://pubmed.ncbi.nlm.nih.gov/32299045
12. Zhou, Y., Lin, C., Ahmed, S., & Patel, R. (2023). Integrating artificial intelligence with clinical decision-making in oncology: Challenges and opportunities. Journal of Cancer Informatics, 22(1), 45–58. https://doi.org/10.1177/11769351231111234
13. Abdeldjouad, F. Z., Brahami, M., & Sabri, M. (2024). Evaluating the effectiveness of artificial intelligence in predicting adverse drug reactions among cancer patients: A systematic review and meta-analysis. arXiv Preprint. https://arxiv.org/abs/2404.05762
14. Aydin, C., & Kalkan, R. (2020). An epigenetic approach to cancer treatment. Global Medical Genetics, 7(1), 3–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410103/
15. Epigenetics and cancer: A comprehensive review. (2023). Asian Pacific Journal of Cancer Biology, 6(2), 101–106. https://waocp.com/journal/index.php/apjcb/article/view/988
16. Feng, R., et al. (2022). Progress in targeting epigenetic modifications in cancer therapy. FEBS Journal, 289(19), 5917–5934. https://febs.onlinelibrary.wiley.com
17. Li, H. C., et al. (2020). Epigenetic modulation as a strategy for cancer treatment. Journal of Molecular Evolution, 88(2), 202–209. https://pubmed.ncbi.nlm.nih.gov
18. Paul, P. K. (2022). Aspects of biosensors with refers to emerging implications of artificial intelligence, big data and analytics: The changing healthcare – A general review. In Next Generation Smart Nano-Bio-Devices (pp. 1–18).
19. Paul, P. K. (2022). Intelligence, big data and analytics: The changing healthcare – A general review. In Next Generation Smart Nano-Bio-Devices, 322, 1.
20. Paul, P. K., Bhuimali, A., Aithal, P. S., Kalishankar, T., & Saavedra, M. R. (2020). Artificial intelligence & cloud computing in environmental systems-towards healthy & sustainable development. International Journal of Inclusive Development, 6(1), 01-08.
21. Paul, P. K., Pradhan, U., Jena, S. K., Bommali, T., Kayyali, M., & Saavedra, R. (2024). Emerging healthcare systems with AI-based medicine, EHRs, VHAs, & precision healthcare: A scientific study. International Journal of Applied Science and Engineering, 12(2), 133-151.
22. Sculier, J. P., Meert, A. P., et al. (2008). Evaluation of third-generation chemotherapies for advanced NSCLC: A systematic review and meta-analysis. Journal of Thoracic Oncology. https://pubmed.ncbi.nlm.nih.gov
23. WJTOG0105 Trial. (n.d.). Long-term comparison of second- vs third-generation chemoradiotherapy for unresectable stage III NSCLC: 10-year results. PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/
24. Comparative clinical study of second- and third-generation platinum-based chemotherapies combined with radiotherapy in NSCLC. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov
25. Predictive scoring for chemotherapy toxicity in older patients with advanced solid tumors. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

26. Meta-analysis of triplet vs doublet chemotherapy regimens in advanced NSCLC: Balancing response and toxicity. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov
27. Advances in cancer chemotherapy: Emerging agents like taxanes and oral platinum drugs. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov

28. Hassanien, M. A., Elsamanoudy, A. Z., Saadany, S. E., Eldakhakhny, B., Tammam, H., Abo-Halawa, N., … Sabry, M. (2024). AI in Oncology: Enhancing diagnostic accuracy and prediction with machine learning. Journal of International Crisis & Risk Communication Research, 7 (S11), 278–291. https://doi.org/10.63278/jicrcr.vi.346
29. Rémy, G., & Lead, H. (2025). Current AI technologies in cancer diagnostics and treatment. Molecular Cancer, 24, Article 159. https://doi.org/10.1186/s12943-025-02369-9
30. Kariri, Y. A. (2025). Update on the treatment of non-small cell lung carcinoma (NSCLC). Journal of Clinical Medicine, 14(19), 6960. https://doi.org/10.3390/jcm14196960
31. Martens, L., & Zhang, P. (2024). The impact of artificial intelligence on health equity in oncology: Scoping review. Journal of Medical Internet Research, 24, e39748. https://doi.org/10.2196/39748
32. Esposito, D., & Jung, M. (2023). Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. Journal of Hematology & Oncology, 16, Article 114. https://doi.org/10.1186/s13045-023-01514-5
33. Reddy, V. P., Mukherjee, S., Mitra, I., & Misra, K. (2016). An experimental and theoretical approach on the kinetics and mechanism for the formation of a four-membered (S,S) chelated Pt(II) complex. RSC Advances, 6(5). https://doi.org/10.1039/C5RA21161A
34. Misra, K., Ghosh, G. K., Mitra, I., & Mukherjee, S. (2015). Interaction of bio-relevant thio-ether and thiols with dinuclear Pd(II) complex: Kinetics, mechanism, bioactivity in aqueous medium, and molecular docking. RSC Advances, 5(3). https://doi.org/10.1039/C4RA14881A
35. Misra, K., Mitra, I., Ghosh, G. K., & Mukherjee, S. (2014). Kinetics and mechanism of biphasic substitution reactions of a platinum(II) complex with thioglycollic acid and 4-methyl-3-thiosemicarbazide in aqueous solution. Transition Metal Chemistry, 39(7), 879–886. https://doi.org/10.1007/s11243-014-9861-6
36. Ghosh, G. K., Misra, K., Linert, W., & Moi, S. C. (2013). Interaction of glutathione with cis-(2-aminomethylpyridine)diaqua platinum(II) perchlorate in aqueous medium: Their kinetics and mechanism. Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry, 43(6), 777–784. https://doi.org/10.1080/15533174.2012.754760